Journal of Endocrinological Investigation

, Volume 31, Issue 11, pp 950–955 | Cite as

Low free plasma levels of retinol-binding protein 4 in insulin-resistant subjects with polycystic ovary syndrome

  • E. Diamanti-Kandarakis
  • S. Livadas
  • S. A. Kandarakis
  • I. Papassotiriou
  • A. Margeli
Original Articles


Background: It has been shown in animals and in humans that retinol-binding protein 4 (RBP4) production from adipose tissue leads to generalized insulin resistance (IR). A more sensitive marker of circulating RBP4 is free plasma RBP4 expressed by RBP4 to transthyretin (TTR) ratio, since in circulation RBP4 is bound to TTR. Aim: To investigate RBP4 levels in insulin-resistant women with polycystic ovary syndrome (PCOS) and to estimate free plasma RBP4 expressed by RBP4/TTR ratio. Subjects and methods: Thirty-five PCOS subjects were compared with 45 controls matched for age and body mass index (BMI). In each subject, fasting values of glucose, insulin, gonadotropins, estradiol, androgens, C-reactive protein (CRP), RBP4, and TTR were determined. Results: PCOS subjects in comparison to controls were more insulin-resistant [homeostasis model assessment for IR (HOMA-IR): 2.6± 0.3 vs 1.9± 0.1, p=0.043], and presented lower RBP4 levels (28.3± 1.1 vs 32.4± 1.2 μg/ml, p=0.021) and RBP4/TTR ratio (0.26± 0.01 vs 0.31± 0.01, p=0.0014). When RBP4 and RBP4/TTR values where stratified according to BMI status (obese, overweight, and lean subjects), it was noticed that both RBP4 and RBP4/TTR values in lean PCOS were significantly lower than in controls (RBP4: 25.0± 5.5 vs 34.1± 9.0 μg/ml, p=0.0063, RBP4/TTR: 0.25± 0.3 vs 0.35± 0.1, p=0.016). No correlation was observed between RBP4 and RBP4/TTR with any hormonal or metabolic parameter including BMI. Conclusions: RBP4 and free plasma RBP4 expressed as RBP4/TTR ratio are statistically and significantly lower in insulin-resistant PCOS subjects in comparison to controls. Therefore, our findings do not confirm a link between IR, neither with RBP4 nor with free plasma RBP4 levels. The significance of these findings remains to be elucidated, since RBP4 might prove to have different actions, like other adipokines, from humans and rodents.

Key Words

Insulin resistance polycystic ovary syndrome (PCOS) petinol-binding protein 4 (RBP4) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84: 4006–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003,52:908–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999, 28: 341–59.PubMedCrossRefGoogle Scholar
  4. 4.
    Reaven GM, Hollenbeck CB, Chen YD. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 1989,32: 52–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006,12: 324–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436: 356–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Graham TE, Yang Q, Blüher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med 2006, 354: 2552–63.PubMedCrossRefGoogle Scholar
  8. 8.
    Minokoshi Y, Kahn, RC, Kahn BB. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. J Biol Chem 2003, 36: 33609–12.CrossRefGoogle Scholar
  9. 9.
    Kim JK, Zisman A, Fillmore JJ, et al. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 2001, 108: 153–60.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Broch M, Vendrell J, Ricart W, Richart C, Fernández-Real JM. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007, 30: 1802–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Cho YM, Youn BS, Lee H, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006, 29: 2457–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Yao-Borengasser A, Varma V, Bodles AM, et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007, 92: 2590–7.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Tan BK, Chen J, Lehnert H, Kennedy R, Randeva HS. Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids. J Clin Endocrinol Metab 2007, 92: 2764–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Weiping L, Qingfeng C, Shikun M, et al. Elevated serum RBP4 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 2006, 30: 283–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Hahn S, Backhaus M, Broecker-Preuss M, et al. Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism. Eur J Endocrin 2007, 157: 201–7.CrossRefGoogle Scholar
  16. 16.
    Janke J, Engeli S, Boschmann M, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006, 55: 2805–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Monaco HL. The transthyretin-retinol binding protein complex. Biochim Biophys Acta 2000, 1482: 65–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Graham TE, Wason CJ, Blüher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 2007,50: 814–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Aeberli I, Biebinger R, Lehmann R, et al. Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J Clin Endocrinol Metab 2007, 92: 4359–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Raila J, Henze A, Spranger J, Möhlig M, Pfeiffer AF, Schweigert FJ. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int 2007,72: 505–11.PubMedCrossRefGoogle Scholar
  21. 21.
    National Institutes of Health Consensus Meeting on PCOS. In: Dunaif A, ed. Current issues in endocrinology and metabolism. Boston: Blackwell Scientific, 1992.Google Scholar
  22. 22.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Naylor HM, Newcomer ME. The structure of human retinal-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 1999, 38: 2647–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Refai E, Dekki N, Yang SN, et al. Transthyretin constitutes a functional component in pancreatic-cell stimulus-secretion coupling. Proc Natl Acad Sci U S A 2005, 102: 17020–5.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Jia W, Wu H, Bao Y, et al. Association of serum retinol binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 2007, Jun 5 [Epub ahead of print]; doi: 10.1210/jc.2007-0209.Google Scholar
  26. 26.
    Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007, 92: 2712–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Silha JV, Nyomba BL, Leslie WD, Murphy LJ. Ethnicity, insulin resistance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care 2007, 30: 286–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89: 1 273–6.Google Scholar
  29. 29.
    Schweigert FJ. Inflammation-induced changes in the nutritional biomarkers serum retinol and carotenoids. Curr Opin Clin Nutr Metab Care 2001, 4: 477–81.PubMedCrossRefGoogle Scholar
  30. 30.
    Stephensen CB. Vitamin A, infection, and immune function. Annu Rev Nutr 2001, 21: 167–92.PubMedCrossRefGoogle Scholar
  31. 31.
    Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006, 21: 1426–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Vgontzas AN, Trakada G, Bixler EO, et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006, 55: 1076–82.PubMedCrossRefGoogle Scholar
  33. 33.
    Lee JH, Chan L, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting leptin administration: cross-sectional and interventional study in normal, insulin-resistant and diabetic subjects. J Clin Endocrinol Metab 2003, 88: 4848–56.PubMedCrossRefGoogle Scholar
  34. 34.
    Ukkola O. Resistin—a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinology 2002, 147: 571–4.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2008

Authors and Affiliations

  • E. Diamanti-Kandarakis
    • 1
  • S. Livadas
    • 1
  • S. A. Kandarakis
    • 2
  • I. Papassotiriou
    • 2
  • A. Margeli
    • 2
  1. 1.Endocrine Section, First Department of Medicine, Laiko General HospitalUniversity of Athens Medical SchoolAthensGreece
  2. 2.Department of Clinical Biochemistry“Aghia Sophia” Children’s HospitalAthensGreece

Personalised recommendations